Genetic determinants in ischemic heart disease
Wojtczak A, Skretkowicz J.
Department of Pharmacogenetics,
Medical University of Lódz,
90-151 Lódz,
1 Muszynskiego St., Poland.
Acta Pol Pharm. 2008 Sep-Oct;65(5):607-10.


The present paper is a review of current knowledge about the relations between gene polymorphism and predisposition for ischemic heart disease. Many studies investigate polymorphic variants of genes whose protein products contribute to the genesis and development of atherosclerosis of coronary arteries, thrombogenesis and fibrinolysis and other processes significant for the progression of ischemic heart disease. In ischemic heart disease the most often analyzed genes are those connected with metabolism of lipids, the coagulation and fibrinolytic system and the renin-angiotensin-aldosterone system. Factors of inflammation (cytokines, TNF), proliferation of smooth muscles cells and vasoactivation are also important. Manifestation of the illness is connected with accumulation of several genetic determinants, while the clinical picture is additionally modified by environmental factors. Studies of genetic etiopathogenesis of ischemic heart disease may result in effective prevention and treatment in particular patients.
Liberal Eugenics
'Designer babies'
Procreative liberty
Personal genomics
Genetic enhancement
Human self-domestication
Germline genetic engineering
Preimplantation genetic diagnosis
Beneficence, determinism and justice
'The Principle of Procreative Beneficence'
Genetic risk factors for early heart attacks

and further reading

BLTC Research
Utopian Surgery?
The Good Drug Guide
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
MDMA: Utopian Pharmacology
Critique of Huxley's Brave New World